Table 1 |
||||||
|
Subject plasma levels of EBV IgG, EBV IgM and EBV DNA before and during HMP deployment. |
||||||
|
EBV IgG |
EBV IgM |
EBV DNA |
||||
|
SUBJECT |
PRE |
MID |
PRE |
MID |
PRE |
MID |
|
|
||||||
|
1 |
640 |
640 |
NEG |
NEG |
NEG |
NEG |
|
2 |
320 |
640 |
NEG |
NEG |
NEG |
NEG |
|
3 |
2560 |
2560 |
NEG |
NEG |
NEG |
NEG |
|
4 |
0 |
0 |
NEG |
NEG |
NEG |
NEG |
|
5 |
320 |
640 |
POS |
NEG |
NEG |
NEG |
|
6 |
640 |
1280 |
NEG |
NEG |
NEG |
NEG |
|
7 |
1280 |
1280 |
NEG |
NEG |
NEG |
NEG |
|
8 |
640 |
1280 |
NEG |
NEG |
NEG |
NEG |
|
9 |
1280 |
1280 |
NEG |
NEG |
NEG |
NEG |
|
10 |
640 |
1280 |
NEG |
NEG |
NEG |
NEG |
|
|
||||||
|
Antibody levels were determined by immunofluorescence, DNA levels were assessed by PCR. Plasma antibody levels are expressed as titer. Post mission assessments were not performed. |
||||||
|
Crucian et al. BMC Immunology 2007 8:7 doi:10.1186/1471-2172-8-7 |
||||||